Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in ITP therapeutics.

There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets.

There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist.

R&D activity in ITP is significant, with nine products in Phase III development.

Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years.

In deals involving ITP assets, licensing agreements are the most common type of deal globally.

New innovator drugs are expected to enter the ITP market only after the next two years.

Scope

GlobalData’s Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the ITP market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Abbreviations
  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Total Diagnosed Prevalent Cases of Primary ITP in 2023
      • Table Epidemiology Overview: Total Diagnosed Prevalent Cases of Primary ITP in 2023
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in ITP
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drug Profile: Novartis's Revolade/Promacta/Revoleyd/Rebozet
    • Marketed Drug Profile: Amgen's Nplate/Romiplate
    • Marketed Drug Profile: Rigel Pharmaceutical's Tavalisse/Tavlesse
    • Marketed Drug Profile: Swedish Orphan Biovitrum's Doptelet
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Manufacturer Price ($/mg) for Formulations in ITP
    • Marketed Drugs - Manufacturer Price ($/mg)
    • Marketed Drugs - Time to Pricing and Reimbursement for Eltrombopag
    • Marketed Drugs - Time to Pricing and Reimbursement for Romiplostim
    • Marketed Drugs - Time to Pricing and Reimbursement for Fostamatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Avatrombopag
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Mid-to-Late-Stage Pipeline Drugs in ITP
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Hematological Disorders and in ITP
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in ITP
  • Clinical Trials Assessment
    • Clinical Trials in ITP - Historical Overview
    • Clinical Trials in ITP - Overview by Phase
    • Clinical Trials in ITP - Overview by Status
    • Clinical Trials in ITP - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in ITP - Trials with a Virtual Component
    • Clinical Trials in ITP - Geographic Overview
    • Clinical Trials in ITP - Single-Country and Multinational Trials by Region
    • Clinical Trials in ITP - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in ITP - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in ITP - Overview by Endpoint Status
    • Clinical Trials in ITP - Overview by Race and Ethnicity
    • Clinical Trials in ITP - Enrollment Data
    • Clinical Trials in ITP - Overview of Sites by Geography
    • Clinical Trials in ITP - Top 20 Countries for Trial Sites
    • Clinical Trials in ITP - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for ITP
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in ITP by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in ITP
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in ITP
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in ITP
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • About the Authors
  • Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings